Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.77 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639211 | 1.00 | PDE5A (0.77) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3643346 | 0.99 | PDE5A (0.79) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3644763 | 0.91 | PDE5A (0.65) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3644267 | 0.91 | KDM4E (0.66) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3640595 | 0.91 | PDE5A (0.69) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3641690 | 0.91 | CTNNB1 (0.76) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3639927 | 0.90 | CTNNB1 (0.76) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3642524 | 0.90 | KDM4E (0.67) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3643245 | 0.89 | PDE5A (0.63) | PDE5AHRH4KDM4ENPSR1MAPT | |
| SCHEMBL3639826 | 0.89 | PDE5A (0.93) | PDE5AHRH4KDM4ENPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | claimed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | claimed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | claimed |
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| CN-103068393-A | Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase | CLEAVE BIOSCIENCES INC CLEAVE | 2013-04-24 | — | — | CN | disclosed |
| EP-2566480-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | California Institute of Technology (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| CN-101784276-A | Use of compounds for the preparation of antituberculosis agents | SUMMIT CORP PLC | 2010-07-21 | — | — | CN | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | PDE5A 2048/4885HRH4 360/4885KDM4E 3866/4885 |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | VCP, PSMG3, PSMB3 | PDE5A 4147/4885HRH4 4399/4885KDM4E 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.